Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.58 |
| ▸ | RAB9A | P51151 | 2/20 | 0.58 |
| ▸ | NPC1 | O15118 | 1/20 | 0.58 |
| ▸ | THRB | P10828 | 1/20 | 0.58 |
| ▸ | NOX1 | Q9Y5S8 | 1/20 | 0.58 |
| ▸ | DDX3X | O00571 | 6/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 2/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | KDR | P35968 | 2/20 | 0.47 |
| ▸ | KIT | P10721 | 1/20 | 0.47 |
| ▸ | FLT3 | P36888 | 1/20 | 0.47 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.47 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.46 |
| ▸ | NTRK2 | Q16620 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL420363 | 0.90 | CA1 (0.58) | MEN1KMT2AKDM4EALDH1A1RAB9A | |
| SCHEMBL422410 | 0.85 | NPC1 (0.59) | MEN1KMT2AKDM4ERAB9ANPC1 | |
| SCHEMBL423204 | 0.83 | PDGFRB (0.61) | MEN1KMT2ARAB9ANPC1NOX1 | |
| SCHEMBL422926 | 0.82 | AR (0.53) | KDRKITFLT3PDGFRBCA1 | |
| SCHEMBL28456685 | 0.81 | KDR (0.65) | KDRPDGFRBNTRK1NTRK2CA1 | |
| SCHEMBL59604 | 0.80 | KMT2A (0.61) | MEN1KMT2AKDM4EALDH1A1RAB9A | |
| SCHEMBL57825 | 0.79 | KDR (0.61) | KDRKITFLT3PDGFRBNTRK1 | |
| SCHEMBL12346307 | 0.79 | MEN1 (0.53) | MEN1KMT2ARAB9AMAPTHTT | |
| SCHEMBL31212719 | 0.79 | KDR (0.61) | KDRKITFLT3PDGFRBNTRK1 | |
| SCHEMBL59095 | 0.79 | KDR (0.53) | MEN1KMT2AALDH1A1RAB9AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8940778-B2 | Indazole, benzisoxazole, and benzisothiazole kinase inhibitors | ABBVIE INC. (US) | 2015-01-27 | — | — | US | disclosed |
| US-8642776-B2 | Indazole, benzisoxazole, and benzisothiazole kinase inhibitors | ABBVIE INC. (US) | 2014-02-04 | — | — | US | disclosed |
| US-20130245015-A1 | INDAZOLE, BENZISOXAZOLE, AND BENZISOTHIAZOLE KINASE INHIBITORS | ABBVIE INC (US) | 2013-09-19 | — | — | US | disclosed |
| US-20130030189-A1 | INDAZOLE, BENZISOXAZOLE, AND BENZISOTHIAZOLE KINASE INHIBITORS | ABBVIE INC. (US) | 2013-01-31 | — | — | US | disclosed |
| US-8299243-B2 | Indazole, benzisoxazole, and benzisothiazole kinase inhibitors | ABBVIE INC. (US) | 2012-10-30 | — | — | US | disclosed |
| EP-2246333-B1 | Indazole, benzisoxazole, and benzisothiazole kinase inhibitors | ABBOTT LAB (US) | 2012-10-24 | — | — | EP | disclosed |
| US-20120022253-A1 | INDAZOLE, BENZISOXAZOLE, AND BENZISOTHIAZOLE KINASE INHIBITORS | ABBOTT LABORATORIES (US) | 2012-01-26 | — | — | US | disclosed |
| US-8063091-B2 | Indazole, benzisoxazole, and benzisothiazole kinase inhibitors | ABBOTT LABORATORIES (US) | 2011-11-22 | — | — | US | disclosed |
| EP-2246333-A1 | Indazole, benzisoxazole, and benzisothiazole kinase inhibitors | Abbott Laboratories (US) | 2010-11-03 | — | — | EP | disclosed |
| EP-1638941-B1 | INDAZOLE, BENZISOXAZOLE, AND BENZISOTHIAZOLE KINASE INHIBITORS | ABBOTT LAB (US) | 2010-06-02 | — | — | EP | disclosed |
| US-20090286784-A1 | INDAZOLE, BENZISOXAZOLE, AND BENZISOTHIAZOLE KINASE INHIBITORS | ABBOTT LABORATORIES (US) | 2009-11-19 | — | — | US | disclosed |
| US-7598283-B2 | Indazole, benzisoxazole, and benzisothiazole kinase inhibitors | ABBOTT LABORATORIES, INC. (US) | 2009-10-06 | — | — | US | disclosed |
| US-20080076767-A1 | INDAZOLE, BENZISOXAZOLE, AND BENZISOTHIAZOLE KINASE INHIBITORS | ABBVIE INC. | 2008-03-27 | — | — | US | disclosed |
| US-7297709-B2 | Indazole, benzisoxazole, and benzisothiazole kinase inhibitors | ABBOTT LABORATORIES (US) | 2007-11-20 | — | — | US | disclosed |
| US-20050020603-A1 | Indazole, benzisoxazole, and benzisothiazole kinase inhibitors | ABBVIE INC. | 2005-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120022253-A1 | INDAZOLE, BENZISOXAZOLE, AND BENZISOTHIAZOLE KINASE INHIBITORS | ABL1, BLK, BTK | MEN1 2549/4885KMT2A 1422/4885KDM4E 898/4885 |
| US-20130245015-A1 | INDAZOLE, BENZISOXAZOLE, AND BENZISOTHIAZOLE KINASE INHIBITORS | ABL1, BLK, BTK | MEN1 2549/4885KMT2A 1422/4885KDM4E 898/4885 |
| US-20080076767-A1 | INDAZOLE, BENZISOXAZOLE, AND BENZISOTHIAZOLE KINASE INHIBITORS | ABL1, BLK, BTK | MEN1 2549/4885KMT2A 1422/4885KDM4E 898/4885 |
| US-20050020603-A1 | Indazole, benzisoxazole, and benzisothiazole kinase inhibitors | ABL1, BLK, BTK | MEN1 2549/4885KMT2A 1422/4885KDM4E 898/4885 |
| US-20090286784-A1 | INDAZOLE, BENZISOXAZOLE, AND BENZISOTHIAZOLE KINASE INHIBITORS | ABL1, BLK, BTK | MEN1 2549/4885KMT2A 1422/4885KDM4E 898/4885 |
| US-20130030189-A1 | INDAZOLE, BENZISOXAZOLE, AND BENZISOTHIAZOLE KINASE INHIBITORS | ABL1, BLK, BTK | MEN1 2549/4885KMT2A 1422/4885KDM4E 898/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.